Clinical Trial

COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
In local advanced prostate cancer patients with clinically positive metastatic regional lymph node, the optimal treatment is still unanswered. For these patients, radiotherapy combined with hormonal therapy or hormonal therapy alone are recommended. Recently, the reports from NCCB and SEER data showed that radiotherapy combined with hormonal therapy have better survivals than hormonal therapy alone. This randomized phase III trial compare hormonal therapy alone with combined hormone with radiotherapy in clinically pelvic lymph node metastatic prostate cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-08-01; most recent amendment 2023-11-22.
Status change: Recruiting → Active, Not Recruiting 2022-07-07
Trial Details
NCT Number NCT03241537
Lead Sponsor Samsung Medical Center
Conditions Prostate Neoplasm
Enrollment 61 participants
Start Date 2016-01-15
Primary Completion 2026-12-14 (estimated)
Study Completion 2026-12-14 (estimated)
Updated on ClinicalTrials.gov 2023-11-27